Second line treatment of small cell lung cancer: more is better?
@article{ATM12254, author = {Michael S. Humeniuk and Michael John Kelley}, title = {Second line treatment of small cell lung cancer: more is better?}, journal = {Annals of Translational Medicine}, volume = {4}, number = {Suppl 1}, year = {2016}, keywords = {}, abstract = {Extensive stage small cell lung cancer (SCLC) is an aggressive disease that leaves less than 10% of patients alive at 2 years (1).}, issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/12254} }